Philip Lawson1, Stephen Raskin1, Shelly Soffer2, Edith Marom1, Raanan Berger3, Marianne Michal Amitai1, Tehila Kharizman1, Eli Konen1, Eyal Klang1,4. 1. Department of Radiology, The Chaim Sheba Medical Center, Tel Hashomer, Affiliated to Tel Aviv University, Sackler Faculty of Medicine, Ramat Gan, Israel. 2. Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv-Yafo, Israel. 3. Department of Oncology, The Chaim Sheba Medical Center, Tel Hashomer, Affiliated to Tel Aviv University, Sackler Faculty of Medicine, Ramat Gan, Israel. 4. Department of Population Health Science and Policy, Institute for Healthcare Delivery Science, Mount Sinai, New York, United States.
Abstract
OBJECTIVES: We aimed to analyze the association between the onsets of PE and of progressive disease (PD) in CT scans of oncological patients undergoing clinical trials. METHODS: We retrospectively searched our oncological clinical trials database (1/2012 - 6/2017). We retrieved patients who underwent protocol baseline and follow-up CT scans. RECIST 1.1 categories of response were calculated for each scan at interpretation. The entire dataset was searched for reports with incidental PE.For patients with incidental PE, we collected all the scans conducted up to and including the scan with PE. For each scan, we retrieved the recorded RECIST 1.1 category. We excluded patients with PE at baseline.The frequency of incidental PE in oncological clinical trial patients was calculated. For patients with incidental PE, we evaluated the association between PE and PD. RESULTS: During the study period, 1,070 patients underwent 3,818 CTs. The total number of follow-up months was 7,292 months. 18 patients developed incidental PE during follow-up. Thus, the frequency of incidental PE in oncological clinical trial patients was 3% per year of follow-up. Patients with incidental PE underwent 60 scans up to development of PE. Of 42 non-baseline scans, 6/6 (100%) PD showed PE, and 5/36 (13.9%) non-PD showed PE, making PE onset associated with PD onset (p < 0.001). CONCLUSION: In oncological clinical trials, the frequency of incidental PE is 3% per year of follow-up. The onset of incidental PE is linked to the onset of PD. ADVANCES IN KNOWLEDGE: Incidental PE is associated with the onset of disease progression. Radiologists interpret oncological scans should be aware of the association between PE and PD.
OBJECTIVES: We aimed to analyze the association between the onsets of PE and of progressive disease (PD) in CT scans of oncological patients undergoing clinical trials. METHODS: We retrospectively searched our oncological clinical trials database (1/2012 - 6/2017). We retrieved patients who underwent protocol baseline and follow-up CT scans. RECIST 1.1 categories of response were calculated for each scan at interpretation. The entire dataset was searched for reports with incidental PE.For patients with incidental PE, we collected all the scans conducted up to and including the scan with PE. For each scan, we retrieved the recorded RECIST 1.1 category. We excluded patients with PE at baseline.The frequency of incidental PE in oncological clinical trial patients was calculated. For patients with incidental PE, we evaluated the association between PE and PD. RESULTS: During the study period, 1,070 patients underwent 3,818 CTs. The total number of follow-up months was 7,292 months. 18 patients developed incidental PE during follow-up. Thus, the frequency of incidental PE in oncological clinical trial patients was 3% per year of follow-up. Patients with incidental PE underwent 60 scans up to development of PE. Of 42 non-baseline scans, 6/6 (100%) PD showed PE, and 5/36 (13.9%) non-PD showed PE, making PE onset associated with PD onset (p < 0.001). CONCLUSION: In oncological clinical trials, the frequency of incidental PE is 3% per year of follow-up. The onset of incidental PE is linked to the onset of PD. ADVANCES IN KNOWLEDGE: Incidental PE is associated with the onset of disease progression. Radiologists interpret oncological scans should be aware of the association between PE and PD.
Authors: Mizuki Nishino; Jyothi P Jagannathan; Nikhil H Ramaiya; Annick D Van den Abbeele Journal: AJR Am J Roentgenol Date: 2010-08 Impact factor: 3.959
Authors: F Dentali; W Ageno; C Becattini; L Galli; M Gianni; N Riva; D Imberti; A Squizzato; A Venco; G Agnelli Journal: Thromb Res Date: 2010-05-07 Impact factor: 3.944
Authors: Ann Michelle Browne; Carmel Geraldine Cronin; Collette English; Jennifer NiMhuircheartaigh; Joseph M Murphy; John F Bruzzi Journal: J Thorac Oncol Date: 2010-06 Impact factor: 15.609
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Lawrence H Schwartz; Saskia Litière; Elisabeth de Vries; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Lesley Seymour Journal: Eur J Cancer Date: 2016-05-14 Impact factor: 9.162
Authors: A Carmona-Bayonas; P Jiménez-Fonseca; C Font; F Fenoy; R Otero; C Beato; J M Plasencia; M Biosca; M Sánchez; M Benegas; D Calvo-Temprano; D Varona; L Faez; I de la Haba; M Antonio; O Madridano; M P Solis; A Ramchandani; E Castañón; P J Marchena; M Martín; F Ayala de la Peña; V Vicente Journal: Br J Cancer Date: 2017-03-07 Impact factor: 7.640